Antipsychotic drug side effects for persons with intellectual disability

Research in Developmental Disabilities

Volumn 31, Issue 6, 2010, Pages 1570-1576

  Matson, Johnny L ^a   Mahan, Sara ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Antipsychotic; Intellectual disability; Psychotropic medication; Side effects; Tardive dyskinesia

Indexed keywords

CHLORPROMAZINE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; RISPERIDONE;

ABNORMAL INVENTORY MOVEMENT SCALE; ADVERSE OUTCOME; AGITATION; AKATHISIA; ARTICLE; CLINICAL ASSESSMENT TOOL; DYSKINESIA IDENTIFICATION SYSTEM CONDENSED USER SCALE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPERACTIVITY; HYPOMANIA; INSOMNIA; INTELLECTUAL IMPAIRMENT; IRRITABILITY; MANIA; MATSON EVALUATION OF SIDE EFFECTS; PRESCRIPTION; RESTLESSNESS; SIDE EFFECT; SYMPTOMATOLOGY; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; HUMANS; MENTAL RETARDATION; MOVEMENT DISORDERS; PREVALENCE; RISK FACTORS;

EID: 77957121785     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ridd.2010.05.005     Document Type: Article

References (104)

1. Advokat C.D., Mayville E.A., Matson J.L. Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Research in Developmental Disabilities 2000, 21:75-84.
2. Africano-Oliver P., Dickens S., Ahmed Z., Bouras N., Cooray S., Deb S., et al. Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behavior and intellectual disability. Journal of Intellectual Disability Research 2010, 54:17-25.
3. Ahmed Z., Fraser W., Kerr M.P., Kiernan C., Emerson E., Robertson J., et al. Reducing antipsychotic medication in people with a learning disability. British Journal of Psychiatry 2000, 176:42-46.
4. Aman M.G., Madrid A. Atypical antipsychotics in persons with developmental disabilities. Mental Retardation and Developmental Disabilities Research Review 1999, 5:253-263.
5. Arnold L.E. Clinical pharmacological issues in treating psychiatric disorders of patients with mental retardation. Annals of Clinical Psychiatry 1993, 5:189-197.
6. Barnes T.R. A rating scale for drug-induced akathisia. The British Journal of Psychiatry 1989, 154:672-676.
7. Barnes T.R.E. The Barnes Akathesia Rating Scale-Revisited. Journal of Psychopharmacology 2003, 17:365-370.
8. Barnes T.R.E., Braude W.M. Akathesia variants and tardive dyskinesia. Archives of General Psychiatry 1985, 42:874-878.
9. Barnhill J., Hurley A.D. Movement disorders: Things that do go bump in the night. Part II. Mental Health Aspects of Developmental Disabilities 2009, 12:29-32.
10. Bebarta V.S., Kostic M.A., Gonzalez M.G. Managing adverse reactions to psychotropic medications. Pediatric Annals 2005, 34:947-954.
11. Bisconer S.W., Zhang X., Sine L.F. Impact of a psychotropic medication and physical restraint review process on adults with mental retardation, psychiatric diagnoses, and challenging behaviors. Journal of Developmental and Physical Disabilities 1995, 7:123-135.
12. Bodfish J.W., Crawford T.W., Powell S.B., Parker D.E., Golden R.N., Lewis M.H. Compulsions in adults with mental retardation: Prevalence, phenomenology, and co-morbidity with stereotypy and self-injury. American Journal on Mental Retardation 1995, 100:183-192.
13. Bodfish J.W., Newell K.M., Sprague R.L., Harper V.N., Lewis M.H. Dyskinetic movement disorder among adults with mental retardation: Phenomenology and co-occurrence with stereotypy. American Journal on Mental Retardation 1996, 101:118-129.
14. Bostrom A.C., Walker M.K. Validation of tardive dyskinesia as measured on the dyskinesia identification system-Coldwater. Nursing Research 1990, 39:274-279.
15. Brown T., Mu K., Peyton C.G., Rodger S., Stagnitti K., Hutton E., et al. Occupational therapy students' attitudes towards individuals with disabilities: A comparison between Australia, Taiwan, the United Kingdom, and the United States. Research in Developmental Disabilities 2009, 30:1541-1555.
16. Cheung P.P.P., Siu A.M.H. A comparison of patterns of sensory processing in children with and without developmental disabilities. Research in Developmental Disabilities 2009, 30:1468-1480.
17. Cloud L.J., Jinnah H.A. Treatment strategies for dystonia. Expert Opinion on Pharmacotherapy 2010, 11:5-15.
18. Coe D.A., Matson J.L., Russell D.W., Slifer K.J., Capone G.T., Baglio C., et al. Behavior problems of children with Down syndrome and life events. Journal of Autism and Developmental Disorders 1999, 29:149-156.
19. Cohen S., Khan A., Zheng Y., Chiles J. Tardive dyskinesa in the mentally retarded: Comparison of prevalence, risk factors and topography with a schizophrenic population. Acta Psychiatrica Scandinavica 1991, 83:234-237.
20. Correia C., Vincente A.M. Phamacogenetics of risperidone response and induced side effects. Personalized Medicine 2007, 4:271-293.
21. Correll C.U. Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. Journal of the American Academy of Child and Adolescent Psychiatry 2008, 47:9-20.
22. Correll C.U., Manu P., Olshanskiy V., Napolitano B., Kane J.M., Malhorta A.K. Cardiometabolic risk of second-generation antipsychotic medication during first-time use in children and adolescents. Journal of the American Medical Association 2009, 302:1765-1773.
23. Dawson J.E., Matson J.L., Cherry K.E. An analysis of maladaptive behaviors in persons with autism. PDD-NOS, and mental retardation. Research in Developmental Disabilities 1998, 19:439-448.
24. Danki D., Dilbaz N., Okay I.T. Valproate EK olarak düsük doz olanzapin kullanimna dagli siddetli ekstrapiramidal dulgular: Bir olgu. Klinik Psikofarmakoloji Bülteni 2006, 16:42-46.
25. Davis E., Saeed S.A., Antonacci D.J. Anxiety disorders in persons with developmental disabilities: Empirically informed diagnosis and treatment. Psychiatric Quarterly 2008, 79:249-263.
26. Deb S. Medication for behavior problems associated with learning disabilities. Psychiatry 2006, 5:368-371.
27. Deb S., Chaplin S., Sohanpal G., Unwin G., Soni R., Leontre L. The effectiveness of mood stabilizers and antiepileptic medication for the management of behaviour problems in adults with intellectual disability: A systematic review. Journal of Intellectual Disability Research 2008, 52:107-113.
28. Deb S., Unwin G.L. Psychotrophic medication for behaviour problems in people with intellectual disability: A review of the current literature. Current Opinion in Psychiatry 2007, 20:461-466.
29. deLeon J., Greenlee B., Barber J., Sabaawi M., Singh N.N. Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. Research in Developmental Disabilities 2009, 30:613-669.
30. Ellis C.R., Carmanico S.T., Ricketts R.W., Chambers S., Singh Y.N., Singh N.N. Reliability and validity of three rating scales for assessing tardive dyskinesia in individuals with developmental disabilities. Journal of Developmental and Physical Disabilities 1996, 8:391-406.
31. Embregts P.J.C.M., Didden R., Schreuder N., Huitink C., van Nieuwenhuijzen M. Aggressive behavior in individuals with moderate to borderline intellectual disabilities who live in a residential facility: An evaluation of functional variables. Research in Developmental Disabilities 2009, 30:682-688.
32. Ey H., Faure H., Rappard P. Les reactions d'introlerance vis-avis de la chlorpromazine. Encephale 1956, 45:790-796.
33. Farren C.K., Dinan T.G. Dyskinesia in mentally handicapped women: Relationship to level of handicap and neuroleptic exposure. Acta Psychiatrica Scandinavica 1994, 90:210-213.
34. Fenton W.S., Wyatt R.J., McGlashan T.H. Risk factors of spontaneous dyskinesia in schizophrenia. Archives of General Psychiatry 1994, 51:643-650.
35. Fleming I., Caine A., Ahmet S., Smith S. Aspects of the use of psychoactive medication among people with intellectual disabilities who have been resettled from long-stay hospitals into dispersed housing. Journal of Applied Research in Intellectual Disabilities 1996, 9:194-205.
36. Friedman D.L., Kastner T., Plummer A.T., Ruiz M.Q., Henning D. Adverse behavioral effects in individuals with effects in individuals with mental retardation and mood disorders treated in carbamazepine. American Journal on Mental Retardation 1992, 96:541-546.
37. Friedman J.H., Kucharski L.T., Wagner R.L. Tardive dystonia in a psychiatric hospital. Journal of Neurology Neurosurgery and Psychiatry 1987, 50:801-803.
38. Ganesh S., Rao M., Cowie V.A. Akathisia in neuroleptic medicated mentally handicapped subjects. Journal of Intellectual Disability Research 1989, 33:323-329.
39. Giarelli E., Clarke D.L., Catching C., Ratcliffe S.J. Developmental disabilities and behavioral problems among school children in the Western Cape of South Africa. Research in Developmental Disabilities 2009, 30:1297-1305.
40. Granger D.A., Yurkunski J.M., Miller N.H., Swanson J.M., Crinella F.C. Systematic dyskinesia examination of profoundly mentally retarded persons: Cooperation and assessment. American Journal on Mental Deficiency 1987, 92:155-160.
41. Gualtieri C.T., Hawk B. Tardive dyskinesia and other drug-induced movement disorders among handicapped children and youth. Applied Research in Mental Retardation 1980, 1:55-69.
42. Gualtieri C.T., Schroeder S.R., Hicks R.E., Quade D. Tardive dyskinesia in young mentally retarded individuals. Archives of General Psychiatry 1986, 43:335-340.
43. Guy W. ECDEU assessment manual for psychopharmacology 1976, US Government Printing Office, Washington, DC.
44. Handen B.L., Gilchrist R. Treatment of Childhood Disorders 2006, Guilford Press, Inc., New York. E. Mash, R. Barkley (Eds.).
45. Holden B., Gitlesen J.P. Psychotropic medication in adults with mental retardation: Prevalence, and prescription practices. Research in Developmental Disabilities 2004, 25:509-521.
46. Howerton K., Fernandez G., Touchette P.E., Gurbani S., Sandman C.A., Ashurst J., et al. Psychotropic medications in community based individuals with developmental disabilities: Observations o an interdisciplinary team. Mental Health Aspects of Developmental Disabilities 2002, 5:78-86.
47. Jawed S.H., Singh I. Tardive dyskinesia with schizophrenia relapse. Journal of Intellectual Disability Research 1989, 33:331-334.
48. Jenkins R. Use of psychotropic medication in people with a learning disability. British Journal of Nursing 2000, 9:844-850.
49. Kalachnik J.E. Measuring side effects of psychopharmacologic medication in individuals with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews 1999, 5:348-359.
50. Kalachnik J.E., Sprague R.L. The Dyskinesia Identification System Condensed User Scale (DISCUS): Reliability, validity, and a total cut-off for mentally ill and mentally retarded populations. Journal of Clinical Psychology 1993, 49:177-189.
51. Khan B.U. Brief report: Risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults. Journal of Autism and Developmental Disorders 1997, 27:479-489.
52. Kiernan C., Reeves D., Alborz A. The use of antipsychotic drugs with adults with learning difficulties and challenging behaviour. Journal of Intellectual Disability Research 1995, 39:263-274.
53. Kwok H., Cheung P.W.H. Co-morbidity of psychiatric disorder and medical illness in people with intellectual disabilities. Current Opinion in Psychiatry 2007, 20:443-449.
54. Lang R., Rispoli M., Machalicek W., White P.J., Kang S., Pierce N., et al. Treatment of elopement in individuals with developmental disabilities: A systematic review. Research in Developmental Disabilities 2009, 30:670-681.
55. Levitas A.S., Hurley A.D. The history behind the use of antipsychotic medications in persons with intellectual disability. Part II. Mental Health Aspects of Developmental Disabilities 2006, 9:93-101.
56. Lim H.K., Pae C.V., Lee C., Lee C.U. Tardive dystonic symptoms associated with aripiprazole treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:589-590.
57. LoVullo S.V., Matson J.L. Comorbid psychopathology in adults with autism spectrum disorders in intellectual disabilities. Research in Developmental Disabilities 2009, 30:1288-1296.
58. Mansell J. Challenging behaviour: The prospect for change. British Journal of Learning Disabilities 1994, 22:2-5.
59. Marsden C.D., Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychological Medicine 1980, 10:55-72.
60. Matson J.L., Boisjoli J.A. An overview of developments in research on persons with intellectual disabilities. Research in Developmental Disabilities 2009, 30:587-591.
61. Matson J.L., Neal D. Seizures and epilepsy and their relationship to autism spectrum disorders. Research in Autism Spectrum Disorders 2009, 3:999-1005.
62. Matson J.L., Neal D. Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: An overview. Research in Developmental Disabilities 2009, 30:572-586.
63. Matson J.L., Wilkins J. Antipsychotic drugs for aggression in intellectual disability. The Lancet 2008, 371:9-10.
64. Matson J.L., Bamburg J.W., Mayville E.A., Pinkston J., Bielecki J., Kuhn D., et al. Psychopharmacology and mental retardation: A 10 year review (1990-1999). Research in Developmental Disabilities 2000, 21:263-296.
65. Matson J.L., Bamburg J.W., Mayville E.A., Logan J.R. Tardive dyskinesia and developmental disabilities: An examination of demographics and topography in persons with dual diagnosis. The British Journal of Developmental Disabilities 2000, 46:119-130.
66. Matson J.L., Bielecki J., Mayville S.B., Matson M.L. Psychopharmacology research for individuals with mental retardation: Methodological issues and suggestions. Research in Developmental Disabilities 2003, 24:149-157.
67. Matson J.L., Kiely S.L., Bamburg J.W. The effect of stereotypies on adaptive skills as assessed with the DASH-II and Vineland Adaptive Behavior Scales. Research in Developmental Disabilities 1997, 18:471-476.
68. Matson J.L., Mayville E.A., Bielecki J., Barnes W.H., Bamburg J.W., Baglio C.S. Reliability of the Matson Evaluation of Drug Side Effects scale (MEDS). Research in Developmental Disabilities 1998, 19:501-506.
69. Matson J.L., Rush K.S., Hamilton M., Anderson S.J., Bamburg J.W., Baglio C.S., et al. Characteristics of depression as assessed by the diagnostic assessment for the severely handicapped-II (DASH-II). Research in Developmental Disabilities 1999, 20:305-313.
70. Matson J.L., Mayville E.A., Bamburg J.W., Echholdt C.S. An analysis of side-effect profiles of antiseizure medications in persons with intellectual disability using the Matson Evaluation of Drug Side Effects (MEDS). Journal of Intellectual and Developmental Disability 2001, 26:283-295.
71. Matson J.L., Mayville E.A., Bielecki J., Smalls Y., Eckholdt C.S. Tardive dyskinesia associated with metoclopramide in persons with developmental disabilities. Research in Developmental Disabilities 2002, 23:224-233.
72. Matson J.L., Dempsey T., LoVullo S.V., Wilkins J. The effects of intellectual functioning on the range of core symptoms of autism spectrum disorders. Research in Developmental Disabilities 2008, 29:341-350.
73. Matson J.L., Fodstad J.C., Rivet T.T. The convergent and divergent validity of the Matson Evaluation of Drug Side Effects (MEDS) and the dyskinesia identification system: Condensed User Scale (DISCUS). Journal of Intellectual and Developmental Disability 2008, 33:337-344.
74. Matson J.L., Dempsey T., Fodstad J.C. The effect of autism spectrum disorders on adaptive independent living skills in adults with severe intellectual disability. Research in Developmental Disabilities 2009, 30:1203-1211.
75. Matson J.L., Rivet T.T., Fodstad J.C., Dempsey T., Boisjoli J.A. Examination of adaptive behavior differences in adults with autism spectrum disorders and intellectual disability. Research in Developmental Disabilities 2009, 30:1317-1325.
76. Matson J.L., Fodstad J.C., Neal D., Dempsey T., Rivet T.T. Risk factors for tardive dyskinesia in adults with intellectual disability, comorbid psychopathology, and long-term psychotropic use. Research in Developmental Disabilities 2010, 31:108-116.
77. McGillivray J.A., McCabe M.P. Pharmacological management of challenging behavior of individuals with intellectual disabilities. Research in Developmental Disabilities 2004, 25:523-537.
78. Newell K.M., Bodfish J.W., Mahorney S.L., Sprague R.L. Dynamics of lip dyskinesia associated with neuroleptic withdrawal. American Journal on Mental Retardation 2000, 105:260-268.
79. Newell K.M., Ko Y.G., Sprague R.L., Mahorney S.L., Bodfish J.W. Onset of dyskinesia and changes in postural task performance during the course of neuroleptic withdrawal. American Journal on Mental Retardation 2002, 107:270-277.
80. Newell K.M., Sprague R.L. Tardive dyskinesia and coupling constraints in inter-limb tremor. Human Movement Science 1996, 15:237-251.
81. Newell K.M., Wszola B., Sprague R.L., Mahorney S.L., Bodfish J.W. The changing effector pattern of tardive dyskinesia during the course of neuroleptic withdrawal. Experimental and Clinical Psychopharmacology 2001, 9:262-268.
82. Nieuwenhuis-Mark R.E. Diagnosing Alzheimer's dementia in Down syndrome: Problems and possible solutions. Research in Developmental Disabilities 2009, 30:827-838.
83. Pary R.J. Clozapine in three individuals with mild mental retardation and treatment-refractory psychiatric disorders. Mental Retardation 1994, 32:323-327.
84. Pary R.J., Hurley A.D. Monitoring side-effects of psychiatric medicines in patients with intellectual disability. Mental Health Aspects of Developmental Disabilities 2006, 9:128-130.
85. Pyles D.A.M., Muniz K., Cade A., Silva R. A behavioral diagnostic paradigm for integrating behavior-analytic and psychopharmacological interventions for people with a dual diagnosis. Research in Developmental Disabilities 1997, 18:185-214.
86. Rao J.M., Cowie V.A., Mathew B. Tardive dyskinesia in neuroleptic medicated mentally handicapped subjects. Acta Psychiatrica Scandinavica 1987, 76:507-513.
87. Rose E., Bramham J., Young S., Paliokostas E., Xenitidis K. Neuropsychological characteristics of adults with comorbid ADHD and borderline/mild intellectual disability. Research in Developmental Disabilities 2009, 30:496-502.
88. Santosh P.J., Baird G. Psychopharmacology in children and adults with intellectual disability. The Lancet 1999, 354:233-242.
89. Shih C.-H., Hsu N.-Y., Shih C.-T. Assisting people with developmental disabilities to improve pointing efficiency with an Automatic Pointing Assisting Program. Research in Developmental Disabilities 2009, 30:1212-1220.
90. Sprague R.L., Korach M., van Emmerik R.E.A., Newell K.M. Correlations between kinematic and rating scale measures of tardive dyskinesia in a developmental disabled population. The Journal of Nervous and Mental Disease 1993, 181:42-47.
91. Sprague R.L., van Emmerik R.E., Slobounov S.M., Newell K.M. Facial stereotypic movements and tardive dyskinesia in a mentally retarded population. American Journal on Mental Retardation 1996, 100:345-358.
92. Suppes T., Dennehy E.B., Hirschfeld R.M.A., Altshuler L.L., Bowden C.L., Calabrese J.R., et al. The Texas implementation of medication algorithms: Update to the algorithms for treatment of bipolar I disorder. Journal of Clinical Psychiatry 2005, 66:870-886.
93. Taggart L., McMillan R., Lawson A. Women with and without intellectual disability and psychiatric disorders. Journal of Intellectual Disabilities 2008, 12:191-211.
94. Turek I., Kurland A.A., Hanlon T.E., Bohm M. Tardive dyskinesia: Its relation to neuroleptic and antiparkinson drugs. British Journal of Psychiatry 1972, 121:605-612.
95. Tyrer P., Oliver-Africano P.C., Ahmed Z., Bouras N., Cooray S., Deb S., et al. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: A randomised controlled trial. The Lancet 2008, 371:57-63.
96. Uhrbrand L., Faurbye A. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, seserpine and electroconvulsive therapy. Psychopharmacology 1960, 1:408-418.
97. Valdovinos M.G. Brief review of current research in FXS: Implications for treatment with psychotropic medication. Research in Developmental Disabilities 2007, 28:539-545.
98. Valdovinos M.G., Prasa R.A., Alexander M.L. Results of a nation-wide survey evaluating psychotropic medication use in fragile X syndrome. Journal of Developmental and Physical Disabilities 2009, 21:23-37.
99. Valdovinos M.G., Roberts C., Kennedy C.H. Functional analysis of tardive dyskinesia: Implications for assessment and treatment. Journal of Applied Behavior Analysis 2005, 38:239-242.
100. Van der Molen M.J., Van Luit J.E.H., Jongmans M.J., Van der Molen M.W. Memory profiles in children with mild intellectual disabilities: Strengths and weaknesses. Research in Developmental Disabilities 2009, 30:1237-1247.
101. Varley C.K., McClellan J. Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents. Journal of the American Medical Association 2009, 302:1811-1812.
102. Wigal T., Christian D.L., Wigal S.B., Swanson J.M., Crinella F.M., Potkin S., et al. Classification of types of tardive dyskinesia in a developmentally disabled population at a public residential facility. Journal of Developmental and Physical Disabilities 1993, 5:55-69.
103. Yassa R., Nair V., Dimitry R. Prevalence of tardive dystonia. Acta Psychiatrica Scandinavia 1986, 73:629-633.
104. Yen C.-F., Lin J.-D., Loh C.-H., Shi L., Hsu S.-W. Determinants of prescription drug use by adolescents with intellectual disabilities in Taiwan. Research in Developmental Disabilities 2009, 30:1354-1366.